Background Preliminary data suggests that favipiravir might have a role in COVID-19 treatment.
Our aim was to assess the role of favipiravir in the treatment of COVID-19. Methods A …

Incidence and mortality rates of infections caused by Streptococcus pneumoniae (pneumococcus)
are high worldwide and in Hungary among paediatric as well as adult populations. …

Simultaneous effective treatment of critical COVID-19 disease and newly diagnosed high-risk
multiple myeloma with thalidomide, methylprednisolone, tocilizumab and baricitinib: is it …

Background: Preliminary data suggests that favipiravir might have a role in COVID-19 treatment.
Our aim was to assess the role of favipiravir in the treatment of COVID-19. Methods: A …

Data suggests that favipiravir (FVP) could be used against SARS-CoV-2. Our aim was to
investigate the role of FVP in COVID-19 treatment. A prospective sequential cohort study was …

Background: Nearly 10% of COVID-19 cases will require admission to the intensive care
unit (ICU). Our aim was to assess the clinical and microbiological outcomes of secondary …

Objectives Emerging evidence suggests that remdesivir might improve clinical outcome of
high-risk outpatients with COVID-19. Our aim was to evaluate characteristics and outcomes of …

Objectives Our aim was to compare outcomes of hospitalized adults with severe COVID-19
and cytokine storm treated with tocilizumab or baricitinib. Methods A prospective, …

Background: The optimal approach for adult patients hospitalized with severe and critical
coronavirus disease 2019 (COVID-19), non-responsive to antiviral and immunomodulatory …

Baricitinib is considered a first-line treatment for severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2)-infected adult patients with an associated cytokine storm syndrome (…